Low level of MYO1F in clinical tumors is associated with low ICB response. (A) Left: MYO1F gene expression pooled from responder (N = 23) and nonresponder (N = 27) of PRJEB23709_anti–PD-1 datasets. Right: MYO1F gene expression pooled from responder (N = 32) and nonresponder (N = 15) of PRJEB23709_anti–CTLA-4 datasets (TIGER database). P values were analyzed by Wilcoxon signed-rank test, *P < 0.05, **P < 0.01, ***P < 0.001. (B) Kaplan–Meier survival curves of Melanoma-Nathanson_2017_anti_CTLA-4 (TIGER database). P values were analyzed by log-rank test (Mantel-Cox), *P < 0.05, **P < 0.01, ***P < 0.001. (C) Schematic diagram of protein structure of MYO1F and MYO1E. (D)MYO1F and MYO1E gene expression in responder and nonresponder datasets from different immunotherapies datasets (ICBatlas database). (E) Statistic plots of MYO1F and MYO1E gene expression in responder and nonresponder datasets described in D (ICBatlas database). P values were analyzed by one-way ANOVA test, *P < 0.05, **P < 0.01, ***P < 0.001. (F)MYO1F and MYO1E gene expression pooled from tumor tissues and normal tissues of same patient (TCGA database). Pancreatic adenocarcinoma (PAAD): N (tumor) = 4, N (normal) = 4; LIHC: N (tumor) = 50, N (normal) = 50; LUSC: N (tumor) = 51, N (normal) = 51; LUAD: N (tumor) = 58, N (normal) = 58; COAD: N (tumor) = 40, N (normal) = 40. P values were analyzed by nonparametric Wilcoxon matched-pairs signed rank test, *P < 0.05, **P < 0.01, ***P < 0.001. (G) B16F10 was transfected with a control shRNA construct or shRNA-Myo1f construct. After 48 h of treatment, cell lysates were prepared and probed with antibody against MYO1F by immunoblotting. (H) Tumor growth curve over time. MC38 was transfected with a control shRNA construct or shRNA-Myo1f construct, then subcutaneously injected with 1 × 106 cells on C57BL/6 mice (N = 10). Data were analyzed by one-way ANOVA test; ns, no significance. (I) Tumor collection at day 30 after tumor inoculation (N = 10 in each group). Data in H and I represent one experiment of three independent repeats; G represents one experiment of two independent repeats. Source data are available for this figure: SourceData FS1.
Figure S1.

Low level of MYO1F in clinical tumors is associated with low ICB response . (A) Left: MYO1F gene expression pooled from responder (N = 23) and nonresponder (N = 27) of PRJEB23709_anti–PD-1 datasets. Right: MYO1F gene expression pooled from responder (N = 32) and nonresponder (N = 15) of PRJEB23709_anti–CTLA-4 datasets (TIGER database). P values were analyzed by Wilcoxon signed-rank test, *P < 0.05, **P < 0.01, ***P < 0.001. (B) Kaplan–Meier survival curves of Melanoma-Nathanson_2017_anti_CTLA-4 (TIGER database). P values were analyzed by log-rank test (Mantel-Cox), *P < 0.05, **P < 0.01, ***P < 0.001. (C) Schematic diagram of protein structure of MYO1F and MYO1E. (D)MYO1F and MYO1E gene expression in responder and nonresponder datasets from different immunotherapies datasets (ICBatlas database). (E) Statistic plots of MYO1F and MYO1E gene expression in responder and nonresponder datasets described in D (ICBatlas database). P values were analyzed by one-way ANOVA test, *P < 0.05, **P < 0.01, ***P < 0.001. (F)MYO1F and MYO1E gene expression pooled from tumor tissues and normal tissues of same patient (TCGA database). Pancreatic adenocarcinoma (PAAD): N (tumor) = 4, N (normal) = 4; LIHC: N (tumor) = 50, N (normal) = 50; LUSC: N (tumor) = 51, N (normal) = 51; LUAD: N (tumor) = 58, N (normal) = 58; COAD: N (tumor) = 40, N (normal) = 40. P values were analyzed by nonparametric Wilcoxon matched-pairs signed rank test, *P < 0.05, **P < 0.01, ***P < 0.001. (G) B16F10 was transfected with a control shRNA construct or shRNA-Myo1f construct. After 48 h of treatment, cell lysates were prepared and probed with antibody against MYO1F by immunoblotting. (H) Tumor growth curve over time. MC38 was transfected with a control shRNA construct or shRNA-Myo1f construct, then subcutaneously injected with 1 × 106 cells on C57BL/6 mice (N = 10). Data were analyzed by one-way ANOVA test; ns, no significance. (I) Tumor collection at day 30 after tumor inoculation (N = 10 in each group). Data in H and I represent one experiment of three independent repeats; G represents one experiment of two independent repeats. Source data are available for this figure: SourceData FS1.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal